Marinus Pharmaceuticals (NASDAQ:MRNS) Posts Quarterly Earnings Results, Beats Expectations By $0.02 EPS

Marinus Pharmaceuticals (NASDAQ:MRNS) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.42) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.02, reports. Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 446.48%. The company had revenue of $8.54 million during the quarter, compared to analysts’ expectations of $8.95 million.

Marinus Pharmaceuticals Stock Performance

MRNS opened at $0.30 on Thursday. The firm’s fifty day moving average is $1.28 and its two-hundred day moving average is $1.34. The firm has a market cap of $16.65 million, a PE ratio of -0.12 and a beta of 1.26. Marinus Pharmaceuticals has a twelve month low of $0.26 and a twelve month high of $11.26.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Cantor Fitzgerald decreased their price target on Marinus Pharmaceuticals from $13.00 to $4.00 and set an “overweight” rating on the stock in a report on Friday, October 25th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $0.50 target price (down previously from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. Truist Financial downgraded shares of Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. StockNews.com initiated coverage on shares of Marinus Pharmaceuticals in a report on Sunday. They issued a “hold” rating on the stock. Finally, TD Cowen reaffirmed a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Nine research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $4.79.

Institutional Trading of Marinus Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. Renaissance Technologies LLC bought a new position in Marinus Pharmaceuticals during the second quarter worth about $727,000. Vanguard Group Inc. grew its position in shares of Marinus Pharmaceuticals by 5.0% in the 1st quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after purchasing an additional 132,689 shares during the period. Acadian Asset Management LLC bought a new position in Marinus Pharmaceuticals in the second quarter valued at approximately $813,000. Hussman Strategic Advisors Inc. boosted its holdings in shares of Marinus Pharmaceuticals by 14.3% in the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 10,500 shares during the period. Finally, Squarepoint Ops LLC bought a new stake in shares of Marinus Pharmaceuticals during the second quarter worth $206,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.